Mads Krogsgaard Thomsen/LinkedIn
Dec 16, 2025, 16:34
Mads Krogsgaard Thomsen on Novo Nordisk Haemophilia Foundation’s Support for Haemoglobinopathies
Mads Krogsgaard Thomsen, CEO at Novo Nordisk Foundation, shared on LinkedIn:
”Haemophilia and other blood disorders like sickle cell disease and thalasaemia are chronic, debilitating diseases.
As is often the case, global health inequity is very pronounced, with under-diagnosis, under-treament and poor outcomes as a result in many low and middle income countries.
It is therefore a pleasure to announce that Novo Nordisk Foundation is stepping up, both in absolute funding terms, and in adding the haemoglobinopathy disorders to our support to the Novo Nordisk Haemophilia and Haemoglobinopathies Foundation in these areas.”
Read the full announcement here.
Stay updated with Hemostasis Today.
-
Aug 15, 2026, 19:30José Luis Neyro: E4 and DRSP Reduce Hirsutism While Showing Comparable Effects on Thrombin Generation
-
Aug 15, 2026, 19:27Mahmoud Akraym: Don’t Choose Anticoagulation as the Immediate Treatment for Unstable AF
-
Aug 15, 2026, 19:25Ahmed Bennis: DOACs Increase 1-Year Stroke Risk but Reduce MI Risk Compared With Warfarin
-
Aug 15, 2026, 19:24Megan Adediran: An Unwavering Fight for People Living With Haemophilia
-
Aug 15, 2026, 19:23Intravenous Anticoagulation Linked to Worse Early Outcomes After Noncardioembolic Stroke – International Journal of Stroke
-
Aug 15, 2026, 18:03Alejandro González Veliz: Pulmonary Embolism Is Not Always an Anticoagulation-Only Problem
-
Aug 15, 2026, 17:57Ayesha Zia: A New Foundation for Pediatric Pulmonary Embolism Research and Care
-
Aug 15, 2026, 17:50Muhammad Shaheer Bin Faheem: 25 Years of Thromboembolism and Hypertension Mortality
-
Aug 15, 2026, 17:21Bilal Salman։ NETosis as a Therapeutic Target in Inflammation and Thrombosis